Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer
Executive Summary
SFJ Pharmaceuticals has taken on the late-stage clinical development of Merck KGaA's previously stalled MAb abituzumab, sharing the financial risk and evaluating patients with left-sided colorectal cancer.